Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Alberto Fittipaldo"'
Autor:
Luc Thomas, Ioannis Xynos, Caroline Dutriaux, Sarah Williams, Rainer Kunstfeld, Alberto Fittipaldo, Jean-Jacques Grob, Nicole Basset-Seguin, Bernard Guillot, Lisa Licitra, Laurent Mortier, Thomas Jouary, Nicolas Meyer, Brigitte Dréno, Kate Fife, Reinhard Dummer, Johan Hansson, D. Scott Ernst, Axel Hauschild, Paolo A. Ascierto
Publikováno v:
Lancet Oncology
Lancet Oncology, Elsevier, 2015, 16 (6), pp.729-736. ⟨10.1016/S1470-2045(15)70198-1⟩
Lancet Oncology, Elsevier, 2015, 16 (6), pp.729-736. ⟨10.1016/S1470-2045(15)70198-1⟩
International audience; BACKGROUND:The Hedgehog pathway inhibitor vismodegib has shown clinical benefit in patients with advanced basal cell carcinoma and is approved for treatment of patients with advanced basal cell carcinoma for whom surgery is in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b7a66e99a21db5d838836e3f4eb6434
https://doi.org/10.5167/uzh-112967
https://doi.org/10.5167/uzh-112967
Autor:
Michael Flentje, Alberto Fittipaldo, Sabine Semrau, Rudolf M. Huber, Delphine Aubert, Philip Kleine, Rainer Fietkau, Michael Schmidt, Gabriele Beckmann
Publikováno v:
Oncology Research and Treatment. 29:137-142
Background: Concurrent chemoradiotherapy has improved survival in inoperable stage III non-small cell lung cancer (NSCLC). This phase I trial was performed in order to establish a dose recommendation for oral vinorelbine in combination with cisplatin
Autor:
Guillermo López Vivanco, Alberto Fittipaldo, Dominique Grunenwald, Leona Koubková, Aleksandra Szczesna, Grzegorz Ziolo, Maciej Krzakowski, Reury-Perng Perng, Francesco Carpagnano, Swan-Swan Leong, Cecilia De Almeida, Jubrail Dahabreh, Henryk Olechnowicz, Maya Gottfried, Rodryg Ramlau, Delphine Aubert
Publikováno v:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 3(2)
Introduction This phase III trial was conducted in non-small cell lung cancer patients with locally advanced stage II B (only T3N0) III A and III B (only T4 N0). Primary endpoint was 2-year survival; secondary were toxicity, disease-free survival, an
Autor:
Stephen P. Ackland, Alberto Fittipaldo, George Peter Breitbach, Adnan Ezzat, Massimo Lopez, Antonio Antón, Elena Colajori, Carlos Delfino, Donatella Viaro, Anna Efremidis, Kristo Kolaric, Jennifer M. Tursi
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 19(4)
PURPOSE: To determine the relative efficacy of a cyclophosphamide epirubicin and fluorouracil (CEF) regimen compared with an intravenous (IV) cyclophosphamide, methotrexate, and fluorouracil (CMF) combination in metastatic breast cancer. PATIENTS AND
Autor:
Mark König, Maristella Zurlo, Marcello Riggi, Reg R. Hall, Frans M.J. Debruyne, Alberto Fittipaldo, Wim P.J. Witjes, Frank P. Boeminghaus, Claude Schulman
Publikováno v:
European Urology, 36, 576-581
European Urology, 36, pp. 576-581
European Urology, 36, pp. 576-581
Objectives: This European phase III clinical trial was part of an intercontinental study which was closed prematurely by the sponsor. The study was designed to compare the effects o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86a54c4263378b8c6b2cad98aa72e5e2
http://hdl.handle.net/2066/188027
http://hdl.handle.net/2066/188027
Autor:
Walter Bordogna, Limas Kupčinskas, Irina Davidenko, C. Hillenbach, Sufiya Safina, Alberto Fittipaldo, Barbara Klughammer, Giovanni Gerardo Cardellino, Michel Ducreux, Avgust Garin, David Propper, Minesh Jain, John Bridgewater
Publikováno v:
Annals of Oncology. 23:iv7
Introduction Erlotinib, an epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor, is approved in combination with gemcitabine for advanced pancreatic cancer. As the use of biomarkers to guide treatment decisions for targeted therapies is
Autor:
Alim Koşar, Roger Stenling, Marco Raber, C.J. Tyrrell, Göran Roos, M.J. Speakman, Haluk Ataoglu, Lambertus A. Kiemeney, Katja K.H. Aben, Stefania Ferretti, Pietro Cortellini, M. Studen, U. Löhrs, L. Weissbach, Jan H.M. Blom, Giliola Calori, Ahmet Ergün, Richard Sylvester, C.C. Schulman, H. Vogt, Marcello Riggi, Jean M. Marechal, Aydos K, Reg R. Hall, Frans M.J. Debruyne, Hein Van Poppel, Linda de Prijck, Kemal Sarica, M. Cengiz Güven, Yüksel Saran, Volker Müller-Mattheis, Marta Simonazzi, J. Cortvriend, C. Oblak, Theodor Wagner, Mark König, Elmar W. Gerharz, G. Bucci, D. Cotič, Karl Weingärtner, Farhood Alamdari, Hans-Wilhelm Müller-Gärtner, C. Radmayr, Belgin Can, Fritz H. Schröder, Friedhelm Wawroschek, Rita Gatti, B. Tršinar, Maurizio Brausi, J. Fassbinder, Didier Jacqmin, M. Hartmann, Massimo Freschi, S. Corvin, U. Jonas, Patrizio Rigatti, Dorothea Weckermann, Rolf Harzmann, Claus Dieter Gerharz, Sadettin Küpeli, Vincenzo Scattoni, S. Vaage, T.M.T.W. Lock, Ulrich Köhl, R. Bussar-Maatz, Hubertus Riedmiller, Francesco Montorsi, Michael D. Melekos, G. Janetschek, Bora Küpeli, Martin Reinhardt, Guido Orlandini, Rolf Ackermann, K.P. Dieckmann, Alberto Fittipaldo, Claude Schulman, P.A. Dewan, G.E. Schubert, Rüdiger Heicappell, Maristella Zurlo, Luigi F. Da Pozzo, Börje Ljungberg, K. Mann, Wim P.J. Witjes, G. Bartsch, Henning Vosberg, Günay Alçıgır, Frank P. Boeminghaus
Publikováno v:
European Urology. 36:656-657
Autor:
Rainer Fietkau, Alberto Fittipaldo, Michael Flentje, Rudolf M. Huber, D. Aubert, B. Poellinger, G. Beckmann
Publikováno v:
Journal of Clinical Oncology. 23:7302-7302
7302 Background: Standard treatment for inoperable stage III NSCLC consists on chemotherapy (CT) in combination with RT. In this setting, vinorelbine i.v. has demonstrated to be effective and safe together with CDDP and RT (CALGB 9431). A new oral fo
Autor:
Maristella Zurlo, Friedhelm Wawroschek, Hubertus Riedmiller, Francesco Montorsi, Martin Reinhardt, U. Jonas, Luigi F. Da Pozzo, M.J. Speakman, Bora Küpeli, R. Bussar-Maatz, Katja K.H. Aben, G. Bartsch, Theodor Wagner, Farhood Alamdari, Lambertus A. Kiemeney, P.A. Dewan, L. Weissbach, Frank P. Boeminghaus, Henning Vosberg, Jan H.M. Blom, Wim P.J. Witjes, K.P. Dieckmann, Günay Alçıgır, C. Oblak, Kaan Aydos, Claude Schulman, Fritz H. Schröder, M. Hartmann, Patrizio Rigatti, Ahmet Ergün, Alberto Fittipaldo, Michael D. Melekos, G.E. Schubert, Vincenzo Scattoni, Richard Sylvester, C.C. Schulman, Roger Stenling, H. Vogt, Stefania Ferretti, Rüdiger Heicappell, Volker Müller-Mattheis, S. Corvin, Reg R. Hall, Börje Ljungberg, K. Mann, Ulrich Köhl, Alim Koşar, Marcello Riggi, Jean M. Marechal, Karl Weingärtner, Guido Orlandini, Belgin Can, Rolf Ackermann, C.J. Tyrrell, Haluk Ataoglu, Pietro Cortellini, Linda de Prijck, Mark König, Elmar W. Gerharz, Massimo Freschi, Frans M.J. Debruyne, Marco Raber, Hans-Wilhelm Müller-Gärtner, Rolf Harzmann, Claus Dieter Gerharz, Marta Simonazzi, T.M.T.W. Lock, G. Janetschek, B. Tršinar, Maurizio Brausi, Dorothea Weckermann, Didier Jacqmin, Yüksel Saran, Sadettin Küpeli, Göran Roos, G. Bucci, J. Fassbinder, S. Vaage, M. Studen, U. Löhrs, Hein Van Poppel, C. Radmayr, D. Cotič, Rita Gatti, Giliola Calori, Kemal Sarica, M. Cengiz Güven, J. Cortvriend
Publikováno v:
European Urology. 36:659-659
Autor:
Alberto Fittipaldo, Caroline Dutriaux, Jean-Jacques Grob, Nicole Basset-Seguin, Reinhard Dummer, Brigitte Dréno, Sarah Williams, Rainer Kunstfeld, Bernard Guillot, Johan Hansson, Nicolas Meyer, Lisa Licitra, Ioannis Xynos, Thomas Jouary, Laurent Mortier, Kate Fife, Axel Hauschild, Paolo A. Ascierto, D. Scott Ernst
Publikováno v:
Publons
9024 Background: Vismodegib (VISMO) is the first Hh pathway inhibitor approved for use in adults with advanced BCC (aBCC) that is inappropriate for surgery or radiotherapy. While most VISMO-related...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2ec165af155d9399205ce9f7d029908
https://publons.com/publon/29329706/
https://publons.com/publon/29329706/